Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2022 | $35.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
| 11/18/2021 | $15.00 | Buy | Ladenburg Thalmann |
| 8/17/2021 | $39.00 → $35.00 | Outperform | SVB Leerink |
| 7/8/2021 | $39.00 | Outperform | SVB Leerink |
SC 13G - F-star Therapeutics, Inc. (0001566373) (Subject)
SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)
SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
15-12G - F-star Therapeutics, Inc. (0001566373) (Filer)
EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)
EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)
H.C. Wainwright downgraded F-star Therapeutics from Buy to Neutral and set a new price target of $7.00 from $35.00 previously
Ladenburg Thalmann resumed coverage of F-star Therapeutics with a rating of Buy and set a new price target of $15.00
SVB Leerink reiterated coverage of F-star Therapeutics with a rating of Outperform and set a new price target of $35.00 from $39.00 previously
invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MSD Company Will Not be Hosting Q2 2022 Earnings Conference Call Due to the Pending Transaction with invoX Pharma CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE)
Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual MeetingCompany To Host Conference Call Today at 9:00 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced first quarter 2022 financial results and provided a corporate update. "This year is one of the most important yea
Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the European market. EUDA Health Holdings Limited (NASDAQ:EUDA) surged 53.1% to $2.94. Assure Holdings Corp. (NASDAQ:IONM) jumped 41.2% to $6.86. Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 36% to $1.69 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. WW International, Inc. (NASDAQ:WW) shares gained 29.8% to $5.02 despite worse-than-expected Q4 revenue and Q1 guidance below estimates. The company also announced it wi
F-Star Therapeutics Inc (NASDAQ:FSTX) shares are trading higher Tuesday after the company announced clearance for the proposed acquisition by invoX Pharma. What To Know: The Committee on Foreign Investment in the United States (CFIUS) has cleared the previously announced acquisition by invoX Pharma, marking the final required regulatory approval needed to complete the proposed merger. The merger is expected to be completed following the successful completion of the ongoing tender offer. The offer is scheduled to expire Wednesday at 5 p.m. ET. F-Star is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that James Sandy has been appointed as Chief Development Officer, effective today. Mr. Sandy will lead the clinical development and advancement of F-star's pipeline. "We are delighted to welcome James to F-star," said Eliot Forster, CEO of F-star Therapeutics, Inc. "James brings an unparalleled depth of experience in drug development in oncology and a strong track record of enhancing and accelerating clin
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (